Experience of piloting BPaLM/BPaL for DR-TB care at selected sites in Pakistan

BACKGROUND: Pakistan ranks fourth globally in terms of high drug-resistant TB (DR-TB) burden, with approximately one-third of cases resistant to fluoroquinolones. Bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM/BPaL) offers an opportunity for most DR-TB patients to benefit from a shorter,...

Full description

Saved in:
Bibliographic Details
Main Authors: M.A. Khan, A. Ismail, A. Ghafoor, N. Khan, N. Muzaffar, F. Zafar, A. Gupta, S. Foraida, S. Juneja, R. Fatima, A.W. Khan, S. Shahid
Format: Article
Language:English
Published: International Union Against Tuberculosis and Lung Disease (The Union) 2024-11-01
Series:IJTLD Open
Subjects:
Online Access:https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000011/art00006
Tags: Add Tag
No Tags, Be the first to tag this record!